Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006

Antiviral Research

Volumn 82, Issue 1, 2009, Pages 34-41

  Bauer, Katja ^a   Richter, Martina ^a   Wutzler, Peter ^a   Schmidtke, Michaela ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Evolution; Influenza A virus; Neuraminidase inhibitors; Oseltamivir; Resistance; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; VIRUS HEMAGGLUTININ; VIRUS RNA; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELETION MUTANT; ENZYME INHIBITION; GENE DELETION; GERMANY; IC 50; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N2; INFLUENZA VIRUS A H3N2; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RNA ISOLATION; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS PLAQUE;

ANIMALS; CELL LINE; DOGS; ENZYME INHIBITORS; GERMANY; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; VIRAL PROTEINS; ZANAMIVIR;

INFLUENZA A VIRUS;

EID: 62049086175     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.01.006     Document Type: Article

References (58)

1. Abed Y., Bourgault A.M., Fenton R.J., Morley P.J., Gower D., Owens I.J., Tisdale M., and Boivin G. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J. Infect. Dis. 186 (2002) 1074-1080
2. Barr I.G., Hurt A.C., Deed N., Iannello P., Tomasov C., and Komadina N. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res. 75 (2007) 173-176
3. Barr I.G., Hurt A.C., Iannello P., Tomasov C., Deed N., and Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. 73 (2007) 112-117
4. Bauer K., Schrader C., Suess J., Wutzler P., and Schmidtke M. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Res. 75 (2007) 219-226
5. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
6. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894
7. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., and Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280 (2000) 291-300
8. Cheng L.S., Amaro R.E., Xu D., Li W.W., Arzberger P.W., and McCammon J.A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 51 (2008) 3878-3894
9. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., and Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193 (2006) 1626-1629
10. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., and Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 (2007) 249-257
11. Ellis J.S., Alvarez-Aguero A., Gregory V., Lin Y.P., Hay A., and Zambon M.C. Influenza AH1N2 viruses, United Kingdom, 2001-02 influenza season. Emerg. Infect. Dis. 9 (2003) 304-310
12. Escuret V., Frobert E., Bouscambert-Duchamp M., Sabatier M., Grog I., Valette M., Lina B., Morfin F., and Ferraris O. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41 (2008) 25-28
13. Ferraris O., Kessler N., and Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 68 1 (2005) 43-48
14. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998) 1257-1262
15. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
16. Gubareva L.V., Nedyalkova M.S., Novikov D.V., Murti K.G., Hoffmann E., and Hayden F.G. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J. Gen. Virol. 83 (2002) 2683-2692
17. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41 (1999) 95-98
18. Hatakeyama S., Sugaya N., Ito M., Yamazaki M., Ichikawa M., Kimura K., Kiso M., Shimizu H., Kawakami C., Koike K., Mitamura K., and Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297 (2007) 1435-1442
19. Hayden F.G. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 71 (2006) 372-378
20. Hayden F.G., and Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176 (1992) 119-130
21. Hayden F., Klimov A., Tashiro M., Hay A., Monto A., McKimm-Breschkin J., Macken C., Hampson A., Webster R.G., Amyard M., and Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Ther. 10 (2005) 873-877
22. Hoffmann E., Stech J., Guan Y., Webster R.G., and Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146 (2001) 2275-2289
23. Hughes M.T., Matrosovich M., Rodgers M.E., McGregor M., and Kawaoka Y. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J. Virol. 74 (2000) 5206-5212
24. Hurt A.C., Barr I.G., Hartel G., and Hampson A.W. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62 (2004) 37-45
25. Ilyushina N.A., Govorkova E.A., and Webster R.G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 341 (2005) 102-106
26. Ito T., Couceiro J.N., Kelm S., Baum L.G., Krauss S., Castrucci M.R., Donatelli I., Kida H., Paulson J.C., Webster R.G., and Kawaoka Y. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72 9 (1998) 7367-7373
27. Jones D.T., Taylor W.R., and Thornton J.M. The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci. 8 (1992) 275-282
28. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 9436 (2004) 759-765
29. Krumbholz, A., Schmidtke, M., Bergmann, S., Motzke, S., Bauer, K., Stech, J., Dürrwald, R., Wutzler, P., Zell, R., 2009. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J. Gen. Virol. [Epub ahead of print].
30. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., and Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13 5 (2008) pii: 8026
31. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47 (2000) 1-17
32. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
33. McKimm-Breschkin J.L., Selleck P.W., Usman T.B., and Johnson M.A. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13 (2007) 1354-1357
34. Mishin V.P., Novikov D., Hayden F.G., and Gubareva L.V. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J. Virol. 79 (2005) 12416-12424
35. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
36. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
37. Mungall B.A., Xu X., and Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 103 (2004) 195-197
38. Nedyalkova M.S., Hayden F.G., Webster R.G., and Gubareva L.V. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA. J. Infect. Dis. 185 5 (2002) 591-598
39. Puthavathana P., Auewarakul P., Charoenying P.C., Sangsiriwut K., Pooruk P., Boonnak K., Khanyok R., Thawachsupa P., Kijphati R., and Sawanpanyalert P. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J. Gen. Virol. 86 (2005) 423-433
40. Rameix-Welti M.A., Agou F., Buchy P., Mardy S., Aubin J.T., Véron M., van der W.##S., and Naffakh N. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50 (2006) 3809-3815
41. Roberts N.A. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 356 (2001) 1895-1897
42. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
43. Saito R., Li D., Suzuki Y., Sato I., Masaki H., Nishimura H., Kawashima T., Shirahige Y., Shimomura C., Asoh N., Degawa S., Ishikawa H., Sato M., Shobugawa Y., and Suzuki H. High prevalence of amantadine-resistance influenza A (H3N2) in six prefectures, Japan, in the 2005-2006 season. J. Med. Virol. 79 (2007) 1569-1576
44. Schmidtke M., Zell R., Bauer K., Krumbholz A., Schrader C., Suess J., and Wutzler P. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49 (2006) 286-293
45. Schmidtke M., Bauer K., Ludwig N., and Wutzler P. Emergence and phylogenetic relationships of amantadine-resistant human H3N2 influenza A viruses in Germany in the season 2005/2006. Int. J. Antimicrob. Agents 32 (2008) 192-195
46. Schweiger B., Bruns L., and Meixenberger K. Reassortment between human A(H3N2) viruses is an important evolutionary mechanism. Vaccine 24 (2006) 6683-6690
47. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., and Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52 (2008) 3284-3292
48. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188 (2003) 57-61
49. Tamura K., Dudley J., Nei M., and Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24 8 (2007) 1596-1599
50. Wagner R., Matrosovich M., and Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12 (2002) 159-166
51. Ward P., Small I., Smith J., Suter P., and Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 Suppl. 1 (2005) i5-i21
52. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., and Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41 (2003) 742-750
53. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 (2001) 127-133
54. WHO, 2008. Influenza A(H1N1) virus resistance to oseltamivir-last quarter 2007 to 4 April 2008. http://wwwwhoint/csr/disease/influenza/H1N1ResistanceWeb20080403pdf.
55. Wutzler P., Kossow K.D., Lode H., Ruf B.R., Scholz H., and Vogel G.E. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J. Clin. Virol. 31 (2004) 84-91
56. Xu X., Smith C.B., Mungall B.A., Lindstrom S.E., Hall H.E., Subbarao K., Cox N.J., and Klimov A. Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season. J. Infect. Dis. 186 (2002) 1490-1493
57. Zambon M., and Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49 (2001) 147-156
58. Zhang Q., Yang J., Liang K., Feng L., Li S., Wan J., Xu X., Yang G., Liu D., and Yang S. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. J. Chem. Inf. Model. 48 (2008) 1802-1812